Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a feasibility study to assess the effectiveness of cetuximab when administered with
low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and
neck who have progressed on first line chemotherapy other than a cetuximab containing regimen
will be treated with standard of care weekly cetuximab and twice daily low dose oral
cyclophosphamide for 12 weeks.